Investigating the complexity of naloxone distribution: Which policies matter for pharmacies and potential recipients

B-Tier
Journal: Journal of Health Economics
Year: 2024
Volume: 97
Issue: C

Authors (6)

Smart, Rosanna (not in RePEc) Powell, David (RAND) Pacula, Rosalie Liccardo (University of Southern Califor...) Peet, Evan (not in RePEc) Abouk, Rahi (not in RePEc) Davis, Corey S. (not in RePEc)

Score contribution per author:

0.335 = (α=2.01 / 6 authors) × 1.0x B-tier

α: calibrated so average coauthorship-adjusted count equals average raw count

Abstract

Despite efforts to expand naloxone access, opioid-related overdoses remain a significant contributor to mortality. We study state efforts to expand naloxone distribution through pharmacies by reducing the non-monetary costs to prescribers, dispensers, and/or potential recipients of naloxone. We find that laws that only address liability costs have small and insignificant effects on the volume of naloxone dispensed through pharmacies. In contrast, we estimate large effects of laws removing the need for patients to obtain prescriptions from traditional prescribers (e.g., primary care physicians): laws authorizing non-patient-specific prescription distribution and laws granting pharmacists prescriptive authority. We test whether areas designated as primary care shortage areas—where it would be costlier to obtain a prescription—were disproportionately impacted. Shortage areas experienced sharper growth in pharmacy naloxone dispensing in states adopting prescriptive authority policies. These gains were primarily due to those facing low out-of-pocket costs, suggesting that price barriers also must be addressed to increase naloxone purchases.

Technical Details

RePEc Handle
repec:eee:jhecon:v:97:y:2024:i:c:s0167629624000626
Journal Field
Health
Author Count
6
Added to Database
2026-01-28